In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
9 authors at 2 institutions in 1 country.
Vicki Mercado-EvansDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0001-9421-9131 Claude ChewCytometry and Cell Sorting Core, Baylor College of Medicine, Houston, Texas, USA.
Camille SerchejianDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Alexander SaltzmanMass Spectrometry Proteomics Core, Baylor College of Medicine, Houston, Texas, USA.
Marlyd E MejiaDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-4929-6450 Jacob J ZulkDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-3758-5503 Ingrid CornaxDepartment of Pediatrics, UC San Diego, La Jolla, California, USA.
Kathryn A PatrasDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0003-2631-8810 Baylor College of Medicine · USUniversity of California San Diego · US
Funding
Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI DAVID R ROWLEY · 2007 to 2026
$73.9MInitiative for Maximizing Student Development (IMSD) ProgramR25GM056929 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI PEREIRA, FRED A · 1998 to 2023
$12.4MThe Clinical Translational Research Certificate of Added Qualification ProgramT32GM136554 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI Melissa Suter, IGNATIA B VAN DEN VEYVER · 2020 to 2026
$3.0MContribution of immune modulation, metabolism, and microbiota to Group B Streptococcal urinary tract infectionR01DK128053 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI PATRAS, KATY · 2021 to 2025
$2.3MTHERMO SCIENTIFIC Q EXACTIVE HF-X HYBRID QUADRUPOLE-ORBITRAP MASS SPECTROMETERS10OD026804 · OD · BAYLOR COLLEGE OF MEDICINE · PI MALOVANNAYA, ANNA · 2019 to 2019
$717kBaylor College of Medicine Initiative for Maximizing Student DevelopmentT32GM152777 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI PANGAS, STEPHANIE A., PEREIRA, FRED A · 2024 to 2024
$547kBD Biosciences Special Order LSRIIS10RR024574 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI LUMPKIN, ELLEN A · 2009 to 2009
$430kCharacterizing the Impact of Gestational Diabetes on Immunity and Group B Streptococcal Virulence in the Maternal Reproductive TractF31AI167547 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI MERCADO, VICKI · 2022 to 2025
$178kDetermining the role of the vaginal microbiota in microbial and immunological resistance to vaginal pathobiont colonizationF31AI167538 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI MEJIA, MARLYD ELIZABETH · 2022 to 2024
$143kInvestigating phage therapy for the treatment of urinary tract infectionsF31DK136201 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI ZULK, JACOB JEFFREY · 2023 to 2024
$97kNCI NIH HHS P30 CA125123NCRR NIH HHS S10 RR024574NIAID NIH HHS F31 AI167538NIAID NIH HHS F31 AI167547NIDDK NIH HHS F31 DK136201NIDDK NIH HHS R01 DK128053NIGMS NIH HHS R25 GM056929NIGMS NIH HHS T32 GM136554NIGMS NIH HHS T32 GM152777NIH HHS S10 OD026804
6 · The paper itselfAbstract
Urinary neutrophils are a hallmark of urinary tract infection (UTI), yet the mechanisms governing their activation, function, and efficacy in controlling infection remain incompletely understood. Tamm-Horsfall glycoprotein (THP), the most abundant protein in urine, uses terminal sialic acids to bind an inhibitory receptor and dampen neutrophil inflammatory responses. We hypothesized that neutrophil modulation is an integral part of THP-mediated host protection. In a UTI model, THP-deficient mice showed elevated urinary tract bacterial burdens, increased neutrophil recruitment, and more severe tissue histopathological changes compared to WT mice. Furthermore, THP-deficient mice displayed impaired urinary NETosis during UTI. To investigate the impact of THP on NETosis, we coupled
Indexed as
NETosisneutrophilTamm-Horsfall proteinurinary tract infectionuropathogenic E. coli
Identifiers
PMID38370726
PMCPMC10871275
OpenAlexW4391664590
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390